RxDoctor Payments Data

Salomi Rami, DO

Family Medicine · Clarkston, MINPI 1699202713

Payments from drug & device makers

$6,832in general payments, 2019–2025

Across 324 payments — averaging $21.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$930
  • GSK$801
  • Amgen$650
  • Pfizer$384
  • Lilly USA, LLC$367
  • plus $2K from 35 others

What the payments were for

  • Food & beverage$6,832100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,832 in reported general payments places this provider in the 90th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$62,893
Medicare patients
95
Services billed
958

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin71$73,183
MounjaroTirzepatide22$22,281
OzempicSemaglutide12$22,240
RybelsusSemaglutide17$21,367
VraylarCariprazine Hcl11$15,519
MyrbetriqMirabegron18$13,993
EliquisApixaban14$11,605
Bydureon BciseExenatide Microspheres13$11,134
AbrysvoRsv Vacc, Pref A And Pref B/Pf18$5,708
ShingrixVaricella-Zoster Ge/As01b/Pf15$3,341
Icosapent Ethyl12$2,682
Rosuvastatin Calcium113$2,434
Fluticasone-SalmeterolFluticasone Propion/Salmeterol15$2,265
Atorvastatin Calcium162$2,031
Losartan Potassium112$1,947

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,910$43,60729 claims
Lilly USA, LLCMounjaro$367$22,28122 claims
PfizerEliquis, Abrysvo$384$17,31332 claims
AbbVieVraylar, Synthroid$930$16,77029 claims
Astellas Pharma US IncMyrbetriq$132$13,99318 claims
GSKShingrix$801$3,34115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Clarkston

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →